NCT03282136 is a Phase 4 clinical trial of Incretin Effect in Type 2 Diabetes Mellitus, sponsored by University of Campania Luigi Vanvitelli.

Who is sponsoring NCT03282136?

NCT03282136 is sponsored by University of Campania Luigi Vanvitelli.

What drugs are being tested in NCT03282136?

Interventions in NCT03282136: Incretin Effect, Cardiac Resynchronization therapy defibrillator device, SGLT-2 inhibitor.

What condition does NCT03282136 study?

NCT03282136 studies Type 2 Diabetes Mellitus, Heart Failure.

Is NCT03282136 still recruiting?

NCT03282136 is currently completed. Last updated 25 June 2025.

Last reviewed 2025-06-25 · How we verify

NCT03282136

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SGLT2i and Incretin and CRTd.

Completed Phase 4 Last updated 25 June 2025

What this trial tests

Phase 4 trial testing Incretin Effect in Type 2 Diabetes Mellitus in 500 participants. Completed in 1 September 2024.

Timeline

1 September 2017

Primary endpoint
1 September 2024

1 September 2024

Quick facts

Lead sponsor	University of Campania Luigi Vanvitelli
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	500
Start date	1 September 2017
Primary completion	1 September 2024
Estimated completion	1 September 2024
Sites	1 location across Italy

Drugs / interventions tested

Incretin Effect — full drug profile →
Cardiac Resynchronization therapy defibrillator device
SGLT-2 inhibitor — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Heart Failure — all drugs for Heart Failure →

Sponsor

University of Campania Luigi Vanvitelli

Who can join

Adults 18 to 70, any sex, with Type 2 Diabetes Mellitus or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Incretin therapy and sodium-glucose- transporter2 inhibitors (SGLT2i) are a treatment for type 2 diabetes (T2DM) affected by heart failure (HF) and treated with cardiac resynchromization therapy (CRT). In this study the investigators will recruit T2DM patients affected by HF with depressed ejection fraction and treated by CRT. These patients will randomly be treated by incretin v/s SGLT2i vs combined therapy with incretin+SGLT2i (and added to conventional hypoglicemic drugs). In these patients investigators will report at follow up CRT-d responders rate, mortality, and hospital admission for HF worsening. Combined therapy with incretin and SGLT2i may reduce hospital admissions for HF in T2DM v/s incretin and/or SGLT2i therapy (added to conventional hypoglicemic drugs).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart fai
Sardu C, Paolisso P, Sacra C, Santamaria M, et al · · 2018 · cited 52× · PMID 30348145 · DOI 10.1186/s12933-018-0778-9
Effects of Vericiguat on the Mitochondrial Function and Clinical Outcomes in CRT Nonresponders Patients.
Sardu C, D'Onofrio N, Fumagalli C, Balestrieri ML, et al · · 2026 · PMID 41936180 · DOI 10.1016/j.jacadv.2026.102708

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other University of Campania Luigi Vanvitelli trials

Trials by the same sponsor.

NCT07590349 — Personalized Robotic Telerehabilitation for Upper Limb Functional Recovery After Stroke in a Home-Based Setting · NA · not yet recruiting
NCT06718452 — Tinnitus and Treatment With umPEA-LUT · NA · not yet recruiting
NCT07124676 — Prospective Study Comparing Two Classification Systems for Second-degree Vaginal Tears During Spontaneous Childbirth to · not yet recruiting
NCT07425912 — Real-World Evaluation of TouchCare Nano in Pediatric Type 1 Diabetes · active not recruiting
NCT06991816 — The Brain&Senses Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03282136 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Campania Luigi Vanvitelli
Last refreshed: 25 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03282136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing